Case Report: Successful Avatrombopag Treatment for Two Cases of Anti-PD-1 Antibody-Induced Acquired Amegakaryocytic Thrombocytopenia

Xiaofang Tu, Ali Xue, Suye Wu, Mengmeng Jin, Pu Zhao* and Hao Zhang*

Department of Hematology, The Third Affiliated Hospital of Wenzhou Medical University, Wenzhou, China

Background: Anti-PD-1/PD-L1 immunotherapy has achieved impressive responses in multiple types of malignancies in recent years. However, immune-related adverse events (irAEs) occur and limit their continuous clinical use. Among these irAEs, acquired amegakaryocytic thrombocytopenia (AAT) is rare but often clinically serious, life-threatening and refractory to multiple treatment approaches.

Case summary: We reported for the first time the successful treatment of avatrombopag in two cases of anti-PD1 antibody-induced AAT (in particular, one case had progressed to aplastic anemia), which was refractory or intolerant to glucocorticoids, ciclosporin, intravenous immunoglobulin (IVIG), recombinant human thrombopoietin (rh-TPO) and even TPO receptor agonist (TPO-RA) eltrombopag. To date, the two cases manifested as normal platelet counts and are independent of transfusion.

Conclusion: Anti-PD1 antibody-induced AAT occurs with low frequency but is often serious and difficult to manage, for which this study proposed vatrotrbopag as a potential curative and safe approach.

Keywords: immune-related adverse events, acquired amegakaryocytic thrombocytopenia, anti-PD-1 antibody, thrombopoietin receptor agonists, avatrombopag

INTRODUCTION

Programmed cell death protein 1 (PD-1) is a member of the immunoglobulin supergene family that is expressed upon lymphocyte activation in CD4+ and CD8+ T cells, which acts as a natural brake that modulates the T cell response. Blockade of the PD-1/programmed cell death ligand 1 (PD-L1) pathway by monoclonal antibodies has emerged as a highly effective approach to reinvigorate T cells in treating several types of malignancies such as melanoma, lung cancer, renal cell carcinoma, gastric cancer and certain types of lymphoma. However, immune-related adverse events (irAEs) frequently

Abbreviations: PD-1, programmed cell death protein 1; PD-L1, programmed cell death ligand 1; irAEs, immune-related adverse events; AAT, acquired amegakaryocytic thrombocytopenia; ITP, immune thrombocytopenia; rh-TPO, recombinant human thrombopoietin; TPO-RAs, thrombopoietin receptor agonists; IVIG, intravenous immunoglobulin; G-CSF, granulocyte colony-stimulating factors; HSCs, hematopoietic stem cells
occur and can potentially affect all organs, which limits the continued use of anti-PD1/PD-L1 antibodies (De Velasco et al., 2017).

Hematological irAEs induced by anti-PD-1/PD-L1 immunotherapy are much less frequent than those induced with conventional cytotoxic chemotherapy and account for approximately 3.6% of total irAEs with the most common type of neutropenia, autoimmune hemolytic anemia and immune thrombocytopenia each in 26%, followed by pancytopenia or aplastic anemia in 14% (Delanoy et al., 2019; Michot et al., 2019). In particular, a rare hematological disorder, which is called acquired amegakaryocytic thrombocytopenia (AAT), is characterized by severe thrombocytopenia and a complete or nearly complete absence of megakaryocytes in the bone marrow (Agarwal et al., 2006). AAT is distinguished from megakaryocyte maturation disorder in immune thrombocytopenia (ITP). AAT is often clinically serious and life-threatening due to the significantly increased risk of vital organ bleeding. To date, only sporadic cases of anti-PD-1/PD-L1 immunotherapy-induced AAT have been reported. The standard treatment of AAT has not been defined, and the management is often thorny because of their refractoriness to possible treatment choices, including immunosuppressive therapy, rituximab, interleukin-11, recombinant human thrombopoietin (rh-TPO) and even some thrombopoietin receptor agonists (TPO-RAs). As a newly FDA approved TPO-RA for immune ITP, avatrombopag promotes platelet production by stimulating TPO receptor (c-Mpl) with high efficacy and safety (Deng et al., 2021; Gilreath et al., 2021). However, little is known about its effects in the treatment of AAT, especially anti-PD-1/PD-L1 antibody-induced AAT. In this study, we report for the first time the successful treatment of avatrombopag in two patients with anti-PD-1 antibody-induced AAT.

CASE PRESENTATIONS

Patient 1
A 67-year-old male was diagnosed with ureter neoplasm with right hydronephrosis and retroperitoneal lymph node metastasis in May 2020. After three cycles of combined chemotherapy (gemcitabine and carboplatin), the patient was administered tislelizumab at a dose of 200 mg every 3 weeks. Three weeks after the second treatment with tislelizumab, routine blood examination indicated thrombocytopenia with a platelet count of $4.8 \times 10^4/\mu L$. Tislelizumab was discontinued, and rh-TPO was used at a dose of 15,000 U/day for 13 consecutive days, but repeated examination showed a further decreased platelet count of $2.1 \times 10^4/\mu L$. Considering anti-PD-1 antibody-related immune thrombocytopenia, the patient received methylprednisolone 80 mg daily for three consecutive weeks until skin hemorrhages and petechiae appeared on his extremities and abdomen, and the platelet count decreased to $0.5 \times 10^4/\mu L$. Bone marrow morphology showed an almost absence of megakaryocytes with no significant abnormal presentation of other cell lineages. Excluding other possible secondary thrombocytopenia (other immune diseases, drugs, or infections induced thrombocytopenia), anti-PD-1 antibody-induced AAT was considered. Due to the risk of life-threatening bleeding, the patient received intravenous immunoglobulin (IVIG) 20 g/day for 5 days and irregular platelet infusion. Unfortunately, there was still no improvement in his platelet count. The following administration of cyclosporine 100 mg daily was discontinued 1 week later because severe pneumonia occurred.

As a potentially effective strategy, TPO-RAs were considered. Oral eltrombopag 50 mg daily was initiated and lasted for a total of 3 months, but it ended in limited responses. The patient was transitioned to avatrombopag at a dose of 40 mg daily. Surprisingly, the platelet count increased to $2.8 \times 10^4/\mu L$ 2 weeks later and above $10 \times 10^4/\mu L$ 2 months after the avatrombopag initiation. To date, the platelet count of the patient has remained normal (Figure 1), and no obvious adverse effects have been observed.

Patient 2
A 71-year-old female who was diagnosed with bladder cancer received surgical resection of the tumor and four cycles of chemotherapy (gemcitabine and cisplatin) in 2019. Due to the evaluation as a poor prognosis, she was started on treatment with triplezumab 200 mg every 3 weeks. After two courses of treatment, she developed thrombocytopenia with a platelet count of $2.6 \times 10^4/\mu L$. Rh-TPO was given at a dose of 15,000 U daily for 17 consecutive days, and the platelet count returned to $5 \times 10^4/\mu L$. Approximately 1 month later, repeated routine blood examination showed a decreased platelet count of $2.9 \times 10^4/\mu L$. Bone marrow examination demonstrated megakaryophasis, and AAT was diagnosed in the absence of evidence that other causes induced thrombocytopenia. Five days of IVIG (20 g/day) and 2 weeks of rh-TPO (15,000 U/day) were administered, but no response was observed, and the platelet count continuously decreased to $1.5 \times 10^4/\mu L$. Then, she received eltrombopag 50 mg daily but discontinued because of economic considerations and limited responses within 2 weeks.

At 5 months later, the patient developed bleeding on her skin and gums with severe thrombocytopenia (platelet count $0.2 \times 10^4/\mu L$), anemia (hemoglobin 5.7 g/dl) and granulocytopenia (white blood cell count 1.9$\times 10^3/\mu L$). Repeated bone marrow examination suggested multilineage hypoplasia with a near absence of megakaryocytes, and immune-related aplastic anemia was diagnosed. The combination of methylprednisolone (40 mg/day), rh-TPO (15,000 U/day) and granulocyte colony-stimulating factors (G-CSF) (200 U/day) was administered for 2 weeks, and no response was observed. Considering the age and potential immunocompromise, the patient refused the use of cyclosporin.

After another 5 months, the patient agreed to the treatment of avatrombopag because of sustained pancytopenia and accompanying complications. Encouragingly, at a dose of 40 mg daily for 1 month, routine blood examination showed a significant improvement in blood cell count. Two months after the avatrombopag administration, a satisfactory blood cell count was achieved with a platelet count of $9.4 \times 10^4/\mu L$, a hemoglobin count of 10.6 g/dl and a white blood cell count of $3.2 \times 10^3/\mu L$. 
During follow-up, no significant adverse events were observed with continued use of avatrombopag.

**DISCUSSION**

With the widespread application of anti-PD-1/PD-L1 antibodies in multiple malignancies, irAEs have been frequently observed in the clinic. Hematological irAEs, especially AAT, occur with a low frequency, but severe bleeding is often life-threatening. Although immune-related disorders are thought to be causative, the exact underlying pathogenesis remains unclear. The possible mechanisms associated with AAT involve activated T cells (T suppressor activated lymphocytes (Benedetti et al., 1994), T-cell large granular lymphocytes (Rajpurkar et al., 2019)), humoral immunity (anti-TPO antibody (Shiozaki et al., 2000), anti-c-Mpl antibody (Son et al., 2019)) or cytokine (Kimura et al., 1996)-mediated disorders of megakaryocyte generation. For anti-PD-1/PD-L1-induced AAT specifically, the underlying mechanism may be similar to those antitumor responses, which refer to the expansion of the T-cell repertoire. Iyama S et al. suggested that cell-mediated instead of humoral immunity possibly participated in anti-PD-1 antibody-induced AAT in studies where no significant difference was observed in growth effects.
between patient and control plasma samples on BFU-E, CFU-GM and CFU-GEMM (Iyama et al., 2020). The role of affected B cell responses and induced autoantibody production, such as anti-TPO, anti-c-Mpl or platelet-associated IgG, in anti-PD-1/PD-L1-induced AAT is unclear due to the limited number of cases and the absence of related clinical and experimental data.

Published reports demonstrated preserved megakaryocytes in most cases of anti-PD-1/PD-L1-induced immune thrombocytopenia, some of which were successfully treated with glucocorticoids, cyclosporins (IVIGs), rituximab or TPO-RA (Suyama et al., 2021). However, based on the possible different pathogenesis in anti-PD-1/PD-L1-induced AAT, treatment responses greatly varied in limited individuals. Thus, effective or optimal therapeutic choices remain confusing and controversial. Nishino S et al. (Nishino et al., 2018) reported a case with anti-PD-1/PD-L1-induced AAT that responded dramatically to glucocorticoids, while the case provided by Suyama T et al. did not respond to glucocorticoids but was cured by TPO-RA eltrombopag (Suyama et al., 2021). Nevertheless, in the present two cases of this study, tiselizumab/triplezumab-induced AATs were refractory to glucocorticoids, IVIG, rh-TPO and even TPO-RA eltrombopag. In addition, due to the potential risk of infection or tumor progression caused by immunocompromise in patients with malignancies, the application of long-term or strong immunosuppressive therapy was restricted, such as cyclosporin and anti-thymocyte globulin.

Similar to eltrombopag, avatrombopag specifically binds to the TPO receptor (c-Mpl) and stimulates the proliferation and differentiation of megakaryocytes and even hematopoietic stem cells (HSCs), which results in resumed production of platelets. Due to its safety and effectiveness, avatrombopag was approved by the FDA to treat chronic ITP in adults (Provan et al., 2019) and thrombocytopenia in adult patients with chronic liver disease (Shirley, 2018). According to the manufacturer’s instructions, a daily dose of 20–40 mg is recommended for patients with chronic ITP, and the standard length of treatment is not defined. TPO-RAs differ in their specific molecular structure, pharmacokinetic characteristics, binding site and the manner in which they stimulate the TPO receptor. Thus, patients who experience intolerance or lack of efficacy with one TPO-RA may benefit from switching to an alternate TPO-RA (Khellaf et al., 2013; Lakhwani et al., 2017). Surprisingly, by transitioning to avatrombopag, both patients in this study achieved satisfactory hematologic responses. The different responses induced by eltrombopag and avatrombopag in the present cases could also be dose-related, since it has been reported that daily 20 mg doses of avatrombopag produce 3–5 times higher peak platelet counts than daily 75 mg doses of eltrombopag (Al-Samkari and Kuter, 2018). Meanwhile, it is also worth considering whether the duration of treatment affects the outcome, since the length of eltrombopag administration was only 2 weeks, and avatrombopag lasted several months in patient 2. No obvious adverse reactions were observed with continued use of avatrombopag in the two cases, although pooled data from clinical trials in ITP indicated that some patients experienced headache, fatigue, epistaxis, infections, etc.

Of note, because anti-PD-1/PD-L1 antibody-induced immune attack can theoretically affect all types of cells, including HSCs and myeloid progenitors, some AATs may progress to aplastic anemia (Delanoy et al., 2019; Novotny et al., 2017). Based on TPO receptors expressed on HSCs, TPO-RA treatment was associated with multilineage clinical responses in some patients with aplastic anemia (Olnes et al., 2012; Scheinberg, 2018). To our knowledge, the application of avatrombopag in aplastic anemia, particularly anti-PD-1/PD-L1 antibody-induced aplastic anemia, has not been reported. The nearly complete response achieved by avatrombopag in patient 2 with AAT progression into aplastic anemia proposed a promising therapeutic approach for such diseases.

In conclusion, anti-PD-1/PD-L1 antibody-induced AAT is rare but often serious and refractory to multiple treatments. This study proposed avatrombopag as a potential curative and safe approach for such patients with limited efficacy or intolerance to immunosuppressive therapy or other recommended treatments.

### DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding authors.

### ETHICS STATEMENT

The studies involving human participants were reviewed and approved by the Ethical Committee of The Third Affiliated Hospital of Wenzhou Medical University. The patients/participants provided their written informed consent to participate in this study.

### AUTHOR CONTRIBUTIONS

The original manuscript was written by HZ and XT and reviewed by PZ. AX, SW and MJ participated in the treatments for the patients. All authors read and approved the final manuscript.

### ACKNOWLEDGMENTS

We thank the Department of Oncology, The Third Affiliated Hospital of Wenzhou Medical University for the support of tumor-related therapy.
REFERENCES

Agarwal, N., Spahr, J. E., Werner, T. L., Newton, D. L., and Rodgers, G. M. (2006). Acquired Amegakaryocytic Thrombocytopenic Purpura. Am. J. Hematol. 81, 132–135. doi:10.1002/ajh.20510

Al-Samkari, H., and Kuter, D. J. (2018). Relative Potency of the Thrombopoietin Receptor Agonists Eltrombopag, Avatrombopag and Romiplostim in a Patient with Chronic Immune Thrombocytopenia. Br. J. Haematol. 183, 168. doi:10.1111/bjh.15432

Benedetti, F., de Sabata, D., and Perona, G. (1994). T Suppressor Activated Lymphocytes (CD8+/DR+) Inhibit Megakaryocyte Progenitor Cell Differentiation in a Case of Acquired Amegakaryocytic Thrombocytopenic Purpura. Stem cells 12, 205–213. doi:10.1002/stem.530120209

De Velasco, G., Je, Y., Bossé, D., Awad, M. M., Ott, P. A., Moreira, R. B., et al. (2017). Comprehensive Meta-Analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/pd-L1 Inhibitors in Cancer Patients. Cancer Immunol. Res. 5, 312–318. doi:10.1158/2326-6066.CIR-16-0237

Delanoy, N., Michot, J. M., Comont, T., Kramkimel, J., de Velasco, G., et al. (2019). Haematological Immune-Related Adverse Events Induced by Anti-PD-1 or Anti-PD-L1 Immunotherapy: a Descriptive Observational Study. Lancet Haematol. 6, e48–e57. doi:10.1016/S2352-3026(18)30175-3

Deng, J., Hu, H., Huang, F., Huang, C., Huang, Q., Wang, L., et al. (2021). Comparative Efficacy and Safety of Thrombopoietin Receptor Agonists in Adults with Thrombocytopenia: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trial. Front. Pharmacol. 12, 704093. doi:10.3389/fphar.2021.704093

Gileath, J., Lo, M., and Bubalo, J. (2021). Thrombopoietin Receptor Agonist (TPO-RA): Drug Class Considerations for Pharmacists. Drugs 81, 1285–1305. doi:10.1007/s40265-021-01553-7

Iyama, S., Takada, K., Yoshida, M., Takahashi, D., and Kobune, M. (2020). Acquired Amegakaryocytic Thrombocytopenic Purpura Possibly Induced by Anti-PD-1 Antibody. Am. J. Hematol. 99, 1669–1670. doi:10.1002/ajh.32720-004053-y

Khellaf, M., Viallard, J. F., Hamidou, M., Cheze, S., Roudot-Thoraval, F., Lefrere, F., et al. (2013). A Retrospective Pilot Evaluation of Switching Thrombopoietic Receptor-Agonists in Immune Thrombocytopenia. Haematologica 98, 881–887. doi:10.3324/haematol.2012.074633

Kimura, F., Nakamura, Y., Sato, K., Wakimoto, N., Kato, T., Tahara, T., et al. (1996). Cyclic Change of Cytokines in a Patient with Cyclic Thrombocytopenia. Br. J. Haematol. 94, 171–174. doi:10.1046/j.1365-2451.1996.d01-1783.x

Lakhwani, S., Perera, M., Fernández-Fuertes, F., Rías de Paz, M. A., Torres, M., Raya, J. M., et al. (2017). Thrombopoietin Receptor Agonist Switch in Adult Primary Immune Thrombocytopenia Patients: A Retrospective Collaborative Survey Involving 4 Spanish Centres. Eur. J. Haematol. 99, 372–377. doi:10.1111/ejh.12932

Michot, J. M., Lazarovici, J., Tieu, A., Champiat, S., Voisin, A. L., Ebbo, M., et al. (2019). Haematological Immune-Related Adverse Events with Immune Checkpoint Inhibitors, How to Manage? Eur. J. Cancer 122, 72–90. doi:10.1016/j.ejca.2019.07.014

Nishino, S., Kodaka, T., Sawada, Y., Goka, T., Gotoh, Y., Tsumine, H., et al. (2018). Marked Rebound Thrombocytosis in Response to Glucocorticoids in a Patient with Acquired Amegakaryocytic Thrombocytopenia. J. Clin. Exp. Hematol 58, 166–170. doi:10.3960/jdr.18016

Novotráj, J. P., Köhler, B., Max, R., and Egeler, G. (2017). Acquired Amegakaryocytic Thrombocytopenic Purpura Progressing into Aplastic Anemia. Pracne Med. Rep. 118, 147–155. doi:10.4172/23362936.2017.16

Olnes, M. J., Scheinberg, P., Calvo, K. R., Desmond, R., Tang, Y., Dumitriu, B., et al. (2012). Eltrombopag and Improved Hematopoiesis in Refractory Aplastic Anemia. N. Engl. J. Med. 367, 11–19. doi:10.1056/NEJMoa1200931

Provan, D., Arnold, D. M., Bussel, J. B., Chong, B. H., Cooper, N., Gernsheimer, T., et al. (2019). Updated International Consensus Report on the Investigation and Management of Primary Immune Thrombocytopenia. Blood Adv. 3, 3780–3817. doi:10.1182/bloodadvances.2019008112

Ramprakash, M., Buck, S., Lafferty, J., Wakeing, E., Ravindranath, Y., and Sava, S. (2019). Acquired Pure Red Cell Aplasia and Acquired Amegakaryocytic Thrombocytopenia Associated with Clonal Expansion of T-Cell Large Granular Lymphocytes in a Patient with Lipopolysaccharide-Responsive Beige-like Anchor (LRBA) Protein Deficiency. J. Pediatr. Hematol. Oncol. 41, e542–e545. doi:10.1097/MPH.0000000000001292

Scheinberg, P. (2018). Activity of Eltrombopag in Severe Aplastic Anemia. Hematol. Am Soc Hematol Educ Program 2018, 450–456. doi:10.1182/asheducation-2018.1.450

Shiozaki, H., Miyawaki, S., Kuwaki, T., Hagiwara, T., Kato, T., and Miyazaki, H. (2000). Autoantibodies Neutralizing Thrombopoietin in a Patient with Amegakaryocytic Thrombocytopenic Purpura. Blood 95, 2187–2188.

Shirley, M. (2018). Avatrombopag: First Global Approval. Drugs 78, 1163–1168. doi:10.1007/s40265-018-0949-8

Son, B., Park, H. S., Han, H. S., Kim, H. K., Baek, S. W., Yang, Y., et al. (2019). A Case of Acquired Amegakaryocytic Thrombocytopenia with Anti-c-mpl Autoantibody: Comparison with Idiopathic Thrombocytopenic Purpura. Acta Haematol. 142, 239–243. doi:10.1159/000499523

Suyama, T., Hagihara, M., Kubota, N., Osamura, Y., Shinka, Y., and Miyao, N. (2021). Acquired Amegakaryocytic Thrombocytopenia after Durvalumab Administration. J. Clin. Exp. Hematop 61, 53–57. doi:10.3960/jdr.2020.47

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Tu, Xue, Wu, Jin, Zhao and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.